Bristol Myers Squibb announces that the European Medicines Agency (EMA) has validated its application for Opdivo (nivolumab) + Yervoy (ipilimumab) as first-line treatment for adult patients with metastatic colorectal cancer with high microsatellite instability (MSI-H) or DNA mismatch repair (dMMR) deficiency,
The EMA has agreed to consider this application, and will now begin its centralized review process.

We look forward to working with the European Medicines Agency to discuss the introduction of the dual immunotherapy combination of Opdivo and Yervoy in patients with MSI-H/dMMR mRCC across Europe', commented Dana Walker, Global Head of Gastrointestinal and Genitourinary Cancers at Bristol Myers Squibb.

Copyright (c) 2024 CercleFinance.com. All rights reserved.